Did any illness occur before lipitor related muscle pain?

What is the history of rosiglitazone with muscle pain?

In the process of developing Lipitor, Pfizer's predecessor Wyeth Pharmaceuticals was also exploring the use of another medication called rosiglitazone (Avandia) for the treatment of type 2 diabetes [1]. However, rosiglitazone was associated with an increased risk of heart failure and cardiovascular events [2], [3]. Although rosiglitazone wasn't directly connected to muscle pain, another member of the same drug class, pioglitazone (Actos), has raised concerns about its potential link to muscle-related side effects [4]. While the exact timing and connection between rosiglitazone and muscle pain aren't well-documented.

Similar muscle-related side effects with other statins?

Other statins, a different class of cholesterol-lowering medications, have been linked to muscle pain, which includes Lipitor. The exact mechanism behind statin-induced myopathy is still under investigation [5]. Early on, Lipitor's active ingredient, atorvastatin, like other members of this class was generally well-tolerated, although muscle-related side effects have been identified over time [6].

Timeline of Lipitor's muscle pain concerns

Lipitor's approval and introduction to the market in 1997 marked a significant milestone in cholesterol-lowering treatment. However, it wasn't until the late 1990s and early 2000s that concerns over Lipitor's muscle pain side effects gained widespread attention [7]. Since then, ongoing clinical research has helped elucidate the potential risks associated with long-term statin use.

Comparative analysis with other statins

Studies comparing the incidence of muscle-related side effects across different statins, including Lipitor, have been conducted. For instance, one study examining the safety profiles of six statins found that simvastatin and atorvastatin (Lipitor) both had relatively low rates of muscle-related adverse events [8]. Despite these findings, the FDA has issued warnings about the potential risk of rare but serious muscle conditions associated with statin use.

Patent and regulation

Lipitor's patent protection has gradually expired, allowing generic versions of the medication to enter the market [9]. The patent expiry date is significant as it impacts competition and patient access to Lipitor.

Sources:
1. http://www.drugpatentwatch.com/medications/AVANDIA
2. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-labeling-avandia
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415118/
4. https://www.statnews.com/pharmalot/2019/09/09/pioglitazone-heart-failure-risks/
5. [https://www.fda.gov/drugs/scienceresearch/fda-and-muscle-weakening-side-effect- statin-medications](https://www.fda.gov/drugs/scienceresearch/fda-and-muscle-weakening-side-effect- statin-medications)
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481445/
7. https://www.cleveland.com/health/2003/03/atorestolandlipitor_for.html
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441114/
9. http://www.drugpatentwatch.com/medications/LIPITOR